Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626530 · ClinicalTrials.gov registry record · Phase 4
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
A Phase 4 study of Cytomegalovirus Infections and Neutropenia, sponsored by Tufts Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05626530 is a Phase 4 study of Cytomegalovirus Infections and Neutropenia that is actively recruiting participants, run by Tufts Medical Center. The registered enrollment target is 25 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05626530, a Phase 4 study of Cytomegalovirus Infections and Neutropenia, is actively recruiting participants, sponsored by Tufts Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (1)
Massachusetts
- Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626530
The ClinicalTrials.gov registry entry for NCT05626530 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (88% lower). The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT05626530 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05626530 about?
NCT05626530 is a clinical study titled "Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients". This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which L...
What is the current status of trial NCT05626530?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2023-02-02. Estimated completion is 2025-12-15.
What conditions does trial NCT05626530 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Neutropenia, Infection in Solid Organ Transplant Recipients, Antiviral Toxicity.
What interventions are being tested in trial NCT05626530?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT05626530?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626530 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
RECRUITING
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.